Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical breakdown of testosterone cypionate safety signals reported to the FDA Adverse Event Reporting System (FAERS), including cardiovascular events, polycythemia, liver injury, and what the data means for patients on TRT.
Read clinical reviewA complete regulatory timeline of testosterone cypionate, from its 1979 FDA approval through post-market label updates, REMS requirements, and current prescribing guidance, with primary citations throughout.
Read clinical reviewA comprehensive look at testosterone cypionate's regulatory history, FDA-approved label requirements, international scheduling, and post-market safety data. Reviewed by the HealthRX.com medical team.
Read clinical reviewA complete timeline of FDA label updates for testosterone cypionate from 2020 through 2026, including cardiovascular warnings, abuse potential language, polycythemia alerts, and the impact of the TRAVERSE trial on prescribing.
Read clinical reviewA clinical review of testosterone cypionate's regulatory history, FDA label updates, post-market safety data from TRAVERSE, and the next-generation testosterone delivery systems in development.
Read clinical reviewHow the FDA and EMA differ in their approval, labeling, and post-market surveillance of testosterone cypionate for hypogonadism and testosterone replacement therapy.
Read clinical review